Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Zimmer

Designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, a... read more Featured Products: More products

Download Mobile App




Diagnostic Test Aids Detection of Prosthetic Joint Infections

By HospiMedica International staff writers
Posted on 10 Jun 2019
A new test kit detects periprosthetic joint infection (PJI) in the synovial fluid of patients being evaluated for revision surgery.

The Zimmer Biomet (Warsaw, IN, USA) Synovasure Lateral Flow Test Kit is an in-vitro visual immunochromatographic diagnostic assay designed to detect human alpha defensins 1-3 proteins in the synovial fluid of patients who underwent total joint replacements. More...
The test, which takes approximately 10 minutes to complete, is not intended to identify a specific type of infection, but rather to be used in conjunction with other clinical and diagnostic findings to aid in the diagnosis of PJI. Each kit contains a reagent strip with all of the critical components for the assay.

Synovial fluid is first collected with a disposable tube, and is then diluted by adding it to a premeasured dilution buffer. Three free-falling drops of the diluted sample are added to the test device to begin the testing process. The cellular material is first removed in a filtering pad, and the solution then transfers to a buffering pad, where it mixes with a gold conjugate labeled with the anti-defensin antibody. The test mixture then migrates across test and control lines; a test result line will form if the level of alpha defensin in the sample is greater than the cut-off concentration.

“With this test, health care professionals now have an additional option available to aid their clinical assessment as to whether the patient has an infection and requires revision surgery,” said Tim Stenzel, MD, PhD, of the FDA Center for Devices and Radiological Health (CDRH). “Whereas before surgeons may have opted for surgery when the presence of an infection was unclear, with this test they have more information and could potentially reduce patient risk by avoiding unnecessary revision operations for replacement joints.”

Alpha defensins are antimicrobial proteins released by activated neutrophils in response to microbial products or pro-inflammatory cytokines. The polar topology of alpha defensins, with spatially separated charged and hydrophobic regions, allows them to insert themselves into phospholipid membranes so that their hydrophobic regions are buried within the lipid membrane interior and their charged regions interact with anionic phospholipid head groups and water, resulting in the disruption of membrane integrity and function, ultimately leading to the lysis of microorganisms.

Related Links:
Zimmer Biomet


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.